Alpha Tau Medical Warrant
DRTSW
26 hedge funds and large institutions have $989K invested in Alpha Tau Medical Warrant in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 2 closing their positions.
0.25% less ownership
Funds ownership: 5.71% → 5.47% (-0.25%)
7% less funds holding
Funds holding: 28 → 26 (-2)
36% less capital invested
Capital invested by funds: $1.54M → $989K (-$550K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$35.4K |
| 2 |
CCA
Castle Creek Arbitrage
Avon,
Colorado
|
-$11.5K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$8.89K |
| 4 |
EPM
Equitec Proprietary Markets
Chicago,
Illinois
|
-$1.49K |
| 5 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$1.48K |
DRTSW Hedge Fund Activity: Q3 2023 in Review
26 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Alpha Tau Medical Warrant (DRTSW) for Q3 2023, worth a combined $989K — down 36% from $1.54M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of DRTSW and 0 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 0 added.
The largest seller was Polar Asset Management Partners, exiting entirely with an estimated $35.4K sold.
- 26 institutional investors held Alpha Tau Medical Warrant (DRTSW) as of Q3 2023, down from 28 in Q2 2023.
- Funds reported $989K of Alpha Tau Medical Warrant stock for Q3 2023, down 36% quarter-over-quarter.
- 0 funds opened new Alpha Tau Medical Warrant positions in Q3 2023 and 2 closed out, a net change of -2 holders.
- The largest Alpha Tau Medical Warrant seller in Q3 2023 was Polar Asset Management Partners, an estimated $35.4K sold.
Based on aggregated 13F filings for Q3 2023.